glp-1 and afib drugs outperform SGLT-2 drugs for patients with type 2 diabetes Glucagon-Like Peptide-1 Protects Against Atrial

Recent landmark trials, particularly the SELECT study, have provided compelling evidence for cardiovascular benefits in non-diabetic obese patients, potentially reshaping our understanding of obesity treatment paradigms

But approval is usually only granted if youre being prescribed the drug for one of its FDA-approved indications (e.g., Type 2 diabetes versus weight loss, depending on the specific drug)

Ultimately, our research and conversations with experts suggest that electrolyte powder is useful under specific circumstances

Results with compounded medications may differ from clinical trial averages for FDA-approved medications